HOUSTON, TX / ACCESS Newswire / February 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments ...
Accomplished physician-scientist brings more than 30 years of industry leadership experience and CNS drug development expertise. SEATTLE, April 29, 2025 /PRNewswire/ -- Transneural Therapeutics, Inc. ...
Vect-Horus has a clinical-phase solution to a key drug development challenge: crossing the blood–brain barrier (BBB). By targeting receptors on the barrier, Vect-Horus is empowering partners such as ...
An influential hypothesis in neuroscience is that the brain may operate near criticality, a transition zone between ...
Peptide conjugation techniques are advancing CNS delivery of oligonucleotides, addressing blood-brain barrier challenges and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results